These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1022 related articles for article (PubMed ID: 32739652)
1. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652 [TBL] [Abstract][Full Text] [Related]
2. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y; JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489 [TBL] [Abstract][Full Text] [Related]
3. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787 [TBL] [Abstract][Full Text] [Related]
5. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL; Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220 [TBL] [Abstract][Full Text] [Related]
6. Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial. Li Y; Wang X; Bao D; Liao Z; Li J; Han X; Wang H; Xu K; Li Z; Stone GW; Han Y Am Heart J; 2020 Oct; 228():8-16. PubMed ID: 32745734 [TBL] [Abstract][Full Text] [Related]
7. Clopidogrel Versus Aspirin as Monotherapy Following Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Receiving a Drug-Eluting Stent: A Systematic Literature Review and Meta-Analysis. Sibbing D; Nicolas J; Spirito A; Vogel B; Cao D; Stipek W; Kasireddy E; Qian A; Khan I; Mehran R Clin Cardiol; 2024 Sep; 47(9):e24326. PubMed ID: 39206792 [TBL] [Abstract][Full Text] [Related]
8. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567 [TBL] [Abstract][Full Text] [Related]
9. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860 [TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS; Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471 [TBL] [Abstract][Full Text] [Related]
11. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Kang J; Park KW; Lee H; Hwang D; Yang HM; Rha SW; Bae JW; Lee NH; Hur SH; Han JK; Shin ES; Koo BK; Kim HS Circulation; 2023 Jan; 147(2):108-117. PubMed ID: 36342475 [TBL] [Abstract][Full Text] [Related]
12. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW; JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763 [TBL] [Abstract][Full Text] [Related]
13. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838 [TBL] [Abstract][Full Text] [Related]
14. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Helft G; Le Feuvre C; Georges JL; Carrie D; Leclercq F; Eltchaninoff H; Furber A; Prunier F; Sebagh L; Cattan S; Cayla G; Vicaut E; Metzger JP Trials; 2013 Feb; 14():56. PubMed ID: 23433461 [TBL] [Abstract][Full Text] [Related]
16. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study. Shin ES; Jun EJ; Kim B; Won KB; Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Han JK; Kim HS; J Am Heart Assoc; 2023 Apr; 12(8):e026770. PubMed ID: 37042284 [TBL] [Abstract][Full Text] [Related]
17. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related]
18. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW; Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163 [TBL] [Abstract][Full Text] [Related]
19. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Jiang M; You JHS Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]